MET has been found to co-express and/or crosstalk with members of the EGFR family, such as HER2, in breast cancer, leading to oncogenesis and drug resistance via activation of PI3K/Akt and Ras/MAPK pathways [23]. Here, ERBB2 is linked to breast carcinoma.